New data on new and newer drugs at the GU Cancers meeting

Posted on February 14, 2013 by Sitemaster

A whole host of new data on drugs like sipuleucel-T, enzalutamide, abiraterone, and others was available in the poster sessions at the Genitourinary Cancers Ssympisum in Orlando today. … READ MORE …

Filed under: Drugs in development, Management, Treatment | Tagged: , , , , , , , , | 6 Comments »

Adding a TKI to docetaxel + prednisone for men with mCRPC

Posted on March 10, 2011 by Sitemaster

One of the great unanswered questions (so far) is whether adding a tyrosine kinase inhibitor (a TKI) to docetaxel + prednisone can improve outcomes for men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Filed under: Drugs in development, Management, Treatment | Tagged: , , , , , | Leave a comment »

  • Donate

  • PCaI’s ASVSG

    If you are on or thinking about active surveillance (AS) as a way to manage your low-risk prostate cancer, you may want to join Prostate Cancer International’s Active Surveillance Virtual Support Group.

  • CureTalks on PCa

    Our most recent CureTalk on Prostate Cancer (on February 21 this year)  features Eli Van Allen, MD, of the Broad Institute and the Dana-Farber Cancer Center, talking about the new “Metastatic Prostate Cancer Project” and how you can become part of the solution.

    For access to the full list of CureTalks on Prostate Cancer, please click here.

  • Disclaimer

    News and information provided on this site should not be used for diagnosing or treating any health problem or disease.

    The “New” Prostate Cancer InfoLink is intended for informational purposes only. It is not engaged in rendering medical advice or professional services and is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.

  • Hot Posts …

  • … and Archives